Palisade Bio (NASDAQ:PALI) Earns Buy Rating from Analysts at Stifel Nicolaus

Stifel Nicolaus began coverage on shares of Palisade Bio (NASDAQ:PALI) in a research note published on Wednesday, Marketbeat reports. The firm issued a buy rating and a $5.00 price target on the stock.

Other equities research analysts have also issued reports about the company. Citigroup reiterated a “buy” rating on shares of Palisade Bio in a research report on Tuesday, November 11th. Clear Str raised shares of Palisade Bio to a “strong-buy” rating in a research note on Monday, December 29th. Piper Sandler assumed coverage on shares of Palisade Bio in a research report on Monday, December 29th. They set an “overweight” rating and a $25.00 price target on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Palisade Bio in a report on Thursday, January 22nd. Finally, B. Riley Financial began coverage on Palisade Bio in a research report on Friday, January 9th. They set a “buy” rating and a $7.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.25.

Palisade Bio Trading Down 4.3%

PALI stock opened at $1.77 on Wednesday. The firm has a 50 day moving average of $1.86 and a 200-day moving average of $1.58. The firm has a market capitalization of $263.74 million, a P/E ratio of -0.83 and a beta of 1.58. Palisade Bio has a 12 month low of $0.53 and a 12 month high of $2.64.

Hedge Funds Weigh In On Palisade Bio

Hedge funds have recently bought and sold shares of the business. Perceptive Advisors LLC bought a new stake in Palisade Bio during the fourth quarter valued at approximately $28,318,000. Commodore Capital LP purchased a new position in Palisade Bio during the fourth quarter valued at $26,896,000. Janus Henderson Group PLC bought a new stake in Palisade Bio during the fourth quarter valued at about $24,822,000. RA Capital Management L.P. purchased a new stake in Palisade Bio in the fourth quarter worth about $16,742,000. Finally, Eversept Partners LP bought a new position in shares of Palisade Bio in the fourth quarter worth about $12,670,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.